According to the latest filing from the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company Curis Inc plan to resell their ordinary shares in the open market in an irregular and batch-by-batch manner.

The total number of shares proposed for sale this time can reach up to 107,706,700 shares. Such shareholder reduction actions are usually based on individual financial planning needs and do not directly reflect changes in the company's fundamentals. Market participants pointed out that large-scale share resales may have a short-term impact on secondary market liquidity, but the company's R&D progress and industry trends need to be comprehensively evaluated to assess its long-term value. This SEC filing clarifies that the sellers are existing shareholders who are not company entities, and the transactions will be carried out in stages in accordance with securities regulations such as Rule 144.